Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.49 |
| ▸ | LMNA | P02545 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | BRS3 | P32247 | 1/20 | 0.43 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 5/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | OGG1 | O15527 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21839164 | 0.94 | CNR1 (0.48) | KMT2ALMNASMN1; SMN2CNR1CNR2 | |
| SCHEMBL8974321 | 0.89 | CNR1 (0.54) | KMT2ALMNASMN1; SMN2CNR1CNR2 | |
| SCHEMBL16823556 | 0.84 | KMT2A (0.49) | KMT2ALMNASMN1; SMN2KCNN4MEN1 | |
| SCHEMBL19459242 | 0.84 | KMT2A (0.49) | KMT2ALMNASMN1; SMN2CNR1CNR2 | |
| SCHEMBL11842642 | 0.83 | KMT2A (0.47) | KMT2ALMNASMN1; SMN2KCNN4MEN1 | |
| SCHEMBL5877921 | 0.83 | MAPT (0.50) | KMT2ALMNASMN1; SMN2CNR1CNR2 | |
| SCHEMBL15788111 | 0.82 | RAB9A (0.44) | KMT2ALMNASMN1; SMN2MEN1RAB9A | |
| SCHEMBL10107624 | 0.82 | KMT2A (0.47) | KMT2ALMNASMN1; SMN2KCNN4MEN1 | |
| SCHEMBL4610636 | 0.82 | ALDH1A1 (0.40) | KMT2ALMNASMN1; SMN2CNR1CNR2 | |
| SCHEMBL3573740 | 0.82 | CNR1 (0.53) | LMNACNR1CNR2BRS3KCNN4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 206 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637440-B2 | Amide derivative useful as diacylglycerol acyltransferase 2 inhibitor, and use thereof | LG CHEM, LTD. (KR) | 2026-05-26 | — | — | US | disclosed |
| US-12630528-B2 | Amino aryl derivative useful as diacylglycerol acyltransferase 2 inhibitor and use thereof | LG CHEM, LTD. (KR) | 2026-05-19 | — | — | US | disclosed |
| WO-2026099466-A1 | TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS AG (CH) | 2026-05-15 | — | — | WO | disclosed |
| US-20250340528-A1 | TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS AG (CH) | 2025-11-06 | — | — | US | disclosed |
| US-12459915-B2 | Biaryl derivative useful as diacylglycerol acyltransferase 2 inhibitor, and use thereof | LG CHEM, LTD. (KR) | 2025-11-04 | — | — | US | disclosed |
| US-12459920-B2 | Targeted protein degradation | MONTE ROSA THERAPEUTICS AG (CH) | 2025-11-04 | — | — | US | disclosed |
| US-20250243180-A1 | TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS AG (CH) | 2025-07-31 | — | — | US | disclosed |
| CN-114591291-B | Bilastine intermediate compound and preparation method thereof | 鲁南制药集团股份有限公司 | 2025-06-17 | — | — | CN | disclosed |
| EP-4071147-B1 | NOVEL AMINO ARYL DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR AND USE THEREOF | LG CHEMICAL LTD (KR) | 2025-03-26 | — | — | EP | disclosed |
| CN-116056706-B | Biaryl derivatives useful as diacylglycerol acyltransferase 2 inhibitors and uses thereof | 株式会社LG化学 | 2024-12-27 | — | — | CN | disclosed |
| US-20020198233-A1 | Process for the preparation of 4-[1-hydroxy-4-[4-(hydroxydiphenylmethly)-1-piperidinyl]-butyl]-alpha,alpha-dimethylbenzeneacetic acid | DINAMITE DIPHARMA S.P.A. ABBREVIATED DIPHARMA S.P.A. (IT) | 2002-12-26 | — | — | US | disclosed |
| US-20020193410-A1 | Substituted (aminoiminomethyl or aminomethyl) dihydrobenzofurans and benzopyrans | AVENTIS PHARMACEUTICALS INC. | 2002-12-19 | — | — | US | disclosed |
| EP-1260505-A1 | A process for the preparation of 4-[1-hydroxy-4-(4-(hydroxydiphenylmethyl)-1-piperidinyl)-butyl]-alpha, alpha-dimethylbenzeneacetic acid | Dinamite Dipharma S.p.A. (IT) | 2002-11-27 | — | — | EP | disclosed |
| US-20020111495-A1 | Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes | PFIZER INC. | 2002-08-15 | — | — | US | disclosed |
| EP-1229034-A1 | Nicotinamide derivatives and their mimetics as inhibitors of PDE4 isozymes | Pfizer Products Inc. (US) | 2002-08-07 | — | — | EP | disclosed |
| EP-1222182-A2 | SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL) DIHYDROBENZOFURANS AND BENOZOPYRANS | Aventis Pharmaceuticals Inc. (US) | 2002-07-17 | — | — | EP | disclosed |
| CN-1333766-A | Substituted (aminoiminomethyl or aminomethyl) benzoheteroaryl compounds as factor xainhibitors | AVENTIS PHARM PROD INC (US) | 2002-01-30 | — | — | CN | disclosed |
| EP-1140901-A2 | SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL)BENZOHETEROARYL COMPOUNDS AS FACTOR XA INHIBITORS | Aventis Pharmaceuticals Products Inc. (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2001014358-A2 | SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL) DIHYDROBENZOFURANS AND BENOZOPYRANS | AVENTIS PHARMACEUTICALS INC. (DE) | 2001-03-01 | — | — | WO | disclosed |
| WO-2000039087-A2 | SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL)BENZOHETEROARYL COMPOUNDS AS FACTOR XA INHIBITORS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250243180-A1 | TARGETED PROTEIN DEGRADATION | NEK7, NEK1, RIPK1 | KMT2A 3318/4885LMNA 1266/4885SMN1; SMN2 782/4885 |
| US-12459920-B2 | Targeted protein degradation | NEK7, NEK1, RIPK1 | KMT2A 3301/4885LMNA 1246/4885SMN1; SMN2 787/4885 |
| US-12630528-B2 | Amino aryl derivative useful as diacylglycerol acyltransferase 2 inhibitor and use thereof | DGAT2, DGAT1, SOAT2 | KMT2A 889/4885LMNA 3574/4885SMN1; SMN2 4619/4885 |
| US-20250340528-A1 | TARGETED PROTEIN DEGRADATION | NEK7, NEK1, RIPK1 | KMT2A 3318/4885LMNA 1266/4885SMN1; SMN2 782/4885 |
| US-20020111495-A1 | Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes | NOX3, NOX1, NOX4 | KMT2A 3442/4885LMNA 1983/4885SMN1; SMN2 2831/4885 |
| US-12637440-B2 | Amide derivative useful as diacylglycerol acyltransferase 2 inhibitor, and use thereof | DGAT2, DGAT1, DLAT | KMT2A 738/4885LMNA 2744/4885SMN1; SMN2 4700/4885 |
| US-20020193410-A1 | Substituted (aminoiminomethyl or aminomethyl) dihydrobenzofurans and benzopyrans | F2, TFPI, F3 | KMT2A 1193/4885LMNA 711/4885SMN1; SMN2 2200/4885 |
| US-20020198233-A1 | Process for the preparation of 4-[1-hydroxy-4-[4-(hydroxydiphenylmethly)-1-piperidinyl]-butyl]-alpha,alpha-dimethylbenzeneacetic acid | P4HA1, CYP4X1, HRH2 | KMT2A 925/4885LMNA 3086/4885SMN1; SMN2 2554/4885 |
| US-12459915-B2 | Biaryl derivative useful as diacylglycerol acyltransferase 2 inhibitor, and use thereof | DGAT2, DGAT1, LCAT | KMT2A 681/4885LMNA 3698/4885SMN1; SMN2 4793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.